Antiplatelet drug response status does not predict recurrent ischemic events in stable cardiovascular patients: Results of the antiplatelet drug resistances and ischemic events study

Circulation

Volumn 125, Issue 25, 2012, Pages 3201-3210

  Reny, Jean Luc ^a,b   Berdagué, Philippe ^b   Poncet, Antoine ^a   Barazer, Isabelle ^b   Nolli, Séverine ^a   Fabbro Peray, Pascale ^c   Schved, Jean François ^d   Bounameaux, Henri ^a   MacH, François ^a   De Moerloose, Philippe ^a   Fontana, Pierre ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^b Centre Hospitalier Beziers   (France)

^c NÎMES UNIVERSITY HOSPITAL   (France)

^d MONTPELLIER UNIVERSITY HOSPITAL   (France)

Author keywords

aspirin; atherosclerosis; clopidogrel; drug resistance; platelet aggregation; thrombosis

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; THROMBOXANE B2;

ADULT; AGE; ARTICLE; CARDIOVASCULAR DISEASE; DEMOGRAPHY; FEMALE; HEART MUSCLE ISCHEMIA; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; OUTPATIENT; PREDICTION; PRIORITY JOURNAL; SMOKING; THROMBOCYTE FUNCTION; TREATMENT RESPONSE;

AGED; DRUG RESISTANCE, MULTIPLE; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL ISCHEMIA; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PREDICTIVE VALUE OF TESTS; RECURRENCE; SINGLE-BLIND METHOD; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84863208556     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.111.085464     Document Type: Article

References (36)

1. Smith SC Jr, Allen J, Blair SN, Bonow RO, Brass LM, Fonarow GC, Grundy SM, Hiratzka L, Jones D, Krumholz HM, Mosca L, Pasternak RC, Pearson T, Pfeffer MA, Taubert KA. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute. Circulation. 2006;113:2363-2372. (Pubitemid 43947981)
2. Fontana P, Reny JL. New antiplatelet strategies in atherothrombosis and their indications. Eur J Vasc Endovasc Surg. 2007;34:10-17. (Pubitemid 46860186)
3. Krasopoulos G, Brister SJ, Beattie WS, Buchanan MR. Aspirin "resistance" and risk of cardiovascular morbidity: systematic review and meta-analysis. BMJ. 2008;336:195-198. (Pubitemid 351212675)
4. Reny JL, De Moerloose P, Dauzat M, Fontana P. Use of the PFA-100 closure time to predict cardiovascular events in aspirin-treated cardiovascular patients: a systematic review and meta-analysis. J Thromb Haemost. 2008;6:444-450. (Pubitemid 351280111)
5. Combescure C, Fontana P, Mallouk N, Berdague P, Labruyere C, Barazer I, Gris JC, Laporte S, Fabbro-Peray P, Reny JL. Clinical implications of clopidogrel non-response in cardiovascular patients: a systematic review and meta-analysis. J Thromb Haemost. 2010;8:923-933.
6. Gurbel PA, Bliden KP. Durability of platelet inhibition by clopidogrel. Am J Cardiol. 2003;91:1123-1125. (Pubitemid 36514934)
7. Linden MD, Furman MI, Frelinger AL 3rd, Fox ML, Barnard MR, Li Y, Przyklenk K, Michelson AD. Indices of platelet activation and the stability of coronary artery disease. J Thromb Haemost. 2007;5:761-765. (Pubitemid 46563575)
8. Cattaneo M. Resistance to antiplatelet drugs: molecular mechanisms and laboratory detection. J Thromb Haemost. 2007;5(suppl 1):230-237. (Pubitemid 46958838)
9. Fontana P, Berdague P, Castelli C, Nolli S, Barazer I, Fabbro-Peray P, Schved JF, Bounameaux H, Mach F, de Moerloose P, Reny JL. Clinical predictors of dual aspirin and clopidogrel poor responsiveness in stable cardiovascular patients from the ADRIE study. J Thromb Haemost. 2010; 8:2614-2623.
10. Patrono C, Ciabattoni G, Pinca E, Pugliese F, Castrucci G, De Salvo A, Satta MA, Peskar BA. Low dose aspirin and inhibition of thromboxane B2 production in healthy subjects. Thromb Res. 1980;17:317-327. (Pubitemid 10129020)
11. Patrono C, Rocca B. Drug insight: aspirin resistance: fact or fashion? Nat Clin Pract Cardiovasc Med. 2007;4:42-50. (Pubitemid 44971071)
12. Fontana P, Nolli S, Reber G, de Moerloose P. Biological effects of aspirin and clopidogrel in a randomized cross-over study in 96 healthy volunteers. J Thromb Haemost. 2006;4:813-819.
13. Frelinger AL, Li Y, Linden MD, Tarnow I, Barnard MR, Fox ML, Michelson AD. Aspirin "resistance": role of pre-existent platelet reactivity and correlation between tests. J Thromb Haemost. 2008;6: 2035-2044.
14. Aleil B, Ravanat C, Cazenave JP, Rochoux G, Heitz A, Gachet C. Flow cytometric analysis of intraplatelet VASP phosphorylation for the detection of clopidogrel resistance in patients with ischemic cardiovascular diseases. J Thromb Haemost. 2005;3:85-92. (Pubitemid 41647119)
15. Bonello L, Tantry US, Marcucci R, Blindt R, Angiolillo DJ, Becker R, Bhatt DL, Cattaneo M, Collet JP, Cuisset T, Gachet C, Montalescot G, Jennings LK, Kereiakes D, Sibbing D, Trenk D, Van Werkum JW, Paganelli F, Price MJ, Waksman R, Gurbel PA. Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. J Am Coll Cardiol. 2010;56:919-933.
16. Jilma B. Platelet function analyzer (PFA-100): a tool to quantify congenital or acquired platelet dysfunction. J Lab Clin Med. 2001;138: 152-163. (Pubitemid 32812228)
17. Gum PA, Kottke-Marchant K, Welsh PA, White J, Topol EJ. A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol. 2003;41:961-965. (Pubitemid 36315537)
18. Gori AM, Marcucci R, Paniccia R, Giusti B, Fedi S, Antonucci E, Buonamici P, Antoniucci D, Gensini GF, Abbate R. Thrombotic events in high risk patients are predicted by evaluating different pathways of platelet function. Thromb Haemost. 2008;100:1136-1145.
19. Reny JL, Fontana P, Fabbro-Peray P, Laporte S, Van Werkum J, Ten Berg J, Geisler T, Gawaz M, Gurbel P, Alessi MC, Cuisset T, Yong G, Angiolillo D, Campo G, Combescure C. Practical use and limitations of ADP aggregation testing to predict cardiovascular events: design and preliminary results of a meta-analysis on individual patients data: ISTH Congress. J Thromb Haemost. 2011;9:337.
20. Frelinger AL 3rd, Li Y, Linden MD, Barnard MR, Fox ML, Christie DJ, Furman MI, Michelson AD. Association of cyclooxygenase-1-dependent and-independent platelet function assays with adverse clinical outcomes in aspirin-treated patients presenting for cardiac catheterization. Circulation. 2009;120:2586-2596.
21. Hosmer DW, Lemeshow S. Applied Logistic Regression. New York, NY: John Wiley & Sons; 1989.
22. Heagerty PJ, Lumley T, Pepe MS. Time-dependent ROC curves for censored survival data and a diagnostic marker. Biometrics. 2000;56: 337-344. (Pubitemid 30422619)
23. Faraday N, Becker DM, Yanek LR, Herrera-Galeano JE, Segal JB, Moy TF, Bray PF, Becker LC. Relation between atherosclerosis risk factors and aspirin resistance in a primary prevention population. Am J Cardiol. 2006;98:774-779. (Pubitemid 44301012)
24. Becker DM, Segal J, Vaidya D, Yanek LR, Herrera-Galeano JE, Bray PF, Moy TF, Becker LC, Faraday N. Sex differences in platelet reactivity and response to low-dose aspirin therapy. JAMA. 2006;295:1420-1427.
25. Serebruany V, Pokov I, Kuliczkowski W, Chesebro J, Badimon J. Baseline platelet activity and response after clopidogrel in 257 diabetics among 822 patients with coronary artery disease. Thromb Haemost. 2008;100:76-82. (Pubitemid 351948748)
26. Lordkipanidze M, Diodati JG, Schampaert E, Palisaitis DA, Pharand C. Lack of clinical predictiveness of six major platelet function tests used to assess aspirin response in patients with stable coronary artery disease. ISTH Congress. J Thromb Haemost. 2011;9(suppl 2):343.
27. Miyata S, Kada A, Nagatsuka K. Clinical impact of aspirin "resistance" on the secondary prevention of atherothrombosis. ISTH Congress. J Thromb Haemost. 2011;9(suppl 2):257.
28. Snoep JD, Hovens MM, Eikenboom JC, van der Bom JG, Huisman MV. Association of laboratory-defined aspirin resistance with a higher risk of recurrent cardiovascular events: a systematic review and meta-analysis. Arch Intern Med. 2007;167:1593-1599. (Pubitemid 47280339)
29. Snoep JD, Hovens MM, Eikenboom JC, van der Bom JG, Jukema JW, Huisman MV. Clopidogrel nonresponsiveness in patients undergoing percutaneous coronary intervention with stenting: a systematic review and meta-analysis. Am Heart J. 2007;154:221-231. (Pubitemid 47069129)
30. von Hundelshausen P, Weber C. Platelets as immune cells: bridging inflammation and cardiovascular disease. Circ Res. 2007;100:27-40. (Pubitemid 46066771)
31. Barnes PJ. Nuclear factor-kappa b. Int J Biochem Cell Biol. 1997;29: 867-870.
32. Ritchie ME. Nuclear factor-kappab is selectively and markedly activated in humans with unstable angina pectoris. Circulation. 1998;98: 1707-1713. (Pubitemid 28492489)
33. Burnier L, Fontana P, Kwak BR, Angelillo-Scherrer A. Cell-derived microparticles in haemostasis and vascular medicine. Thromb Haemost. 2009;101:439-451.
34. Gresele P, Falcinelli E, Loffredo F, Cimmino G, Corazzi T, Forte L, Guglielmini G, Momi S, Golino P. Platelets release matrix metalloproteinase-2 in the coronary circulation of patients with acute coronary syndromes: possible role in sustained platelet activation. Eur Heart J. 2011;32:316-325.
35. Breet NJ, van Werkum JW, Bouman HJ, Kelder JC, Ruven HJ, Bal ET, Deneer VH, Harmsze AM, van der Heyden JA, Rensing BJ, Suttorp MJ, Hackeng CM, ten Berg JM. Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation. JAMA. 2010;303:754-762.
36. Campo G, Parrinello G, Ferraresi P, Lunghi B, Tebaldi M, Miccoli M, Marchesini J, Bernardi F, Ferrari R, Valgimigli M. Prospective evaluation of on-clopidogrel platelet reactivity over time in patients treated with percutaneous coronary intervention relationship with gene polymorphisms and clinical outcome. J Am Coll Cardiol. 2011;57: 2474-2483.